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Abstract Antimicrobial peptides (AMPs) are short amino acidic sequences with
less than 100 residues. They are the components of the innate immune
system not only in humans but also in plants, insects, and primitive
multicellular organisms. Their role is to counteract the microorganisms,
which could be potentially pathogenic for the host. AMPs active against
viruses, bacteria, fungi, and parasites have been described. Among the
antiparasitic AMPs reported so far, some peptides affect Plasmodium
development in different phases of the biological cycle, from asexual
blood stages to sexual stages in the mosquito, where AMPs can
block ookinetes viability or oocyst formation. AMPs with antimalarial
activity derive from different organisms, especially insects, as well as
amphibians. In malaria research, AMPs have been mainly proposed
for the engineering of mosquitoes or parasites to reduce or interrupt
the malaria parasite transmission. In this chapter, the different classes
of antimalarial AMPs (defensins, cecropins, dermaseptins) or single
peptides (scorpine, melittin, gambicin) are described.
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Chapter 7
Beyond Lysozyme: Antimicrobial Peptides 
Against Malaria
Sarah D’Alessandro, Vivian Tullio, and Giuliana Giribaldi
1  Introduction
Antimicrobial peptides (AMPs) are components of innate immunity, the arm of the 
immune system in charge for the first defense against pathogens, not only in humans 
but also in plants, insects, and primitive multicellular organisms. AMPs are short 
amino acidic sequences with less than 100 residues with a secondary structure 
which can be used for their classification (Table 7.1) (Giuliani et al. 2007).
They have a broad spectrum of activity against many microorganisms like Gram 
positive and negative bacteria, fungi, and protozoa, but also viruses. Furthermore, 
antitumor activity for AMPs has also been reported (Hoskin and Ramamoorthy 
2008).
AMPs have a rapid action (minutes to hours) but they are usually active in the 
micromolar range, at higher doses compared to other antibiotics.
Although the mechanisms of action of the majority of AMPs are not precisely 
defined, interference with membranes is recognized as the main activity. Figure 7.1 
schematizes the most known hypotheses on the mode of action of AMPs on the 
membranes of microorganisms. The nonspecific activity on membranes gives to 
AMPs the advantage that they should be less prone to induce resistance in the target 
organisms, being their mechanism of action not connected to a specific target. 
However, this resistance-proof of AMPs has to be demonstrated. On the other side, 
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a disadvantage of the activity on cell membranes could be potential mammalian cell 
toxicity. This is true for some AMPs (e.g., gramicidin A, see paragraph 2.8), but not 
for others (e.g., some dermaseptin derivatives, see Sect. 2.6), which are specific for 
the membranes of microorganisms. In these cases, the difference in activity could be 
due to differences in lipid composition of membranes (cholesterol proportion or 
fluidity).
Beyond the activity at the membrane level, other intracellular targets such as 
protein or DNA synthesis have also been identified for some AMPs (Brogden 2005).
Due to their ability to penetrate cell membranes, AMPs have been proposed as 
vector for drug delivery (Splith and Neundorf 2011).
AMPs are difficult to be classified due to their huge diversity. The classifica-
tions can be based on different features, including amino acidic sequence (e.g., 
presence of cysteine residues, prevalence of particular amino acids, and presence 
of conserved sequences), membrane activity, secondary structure, and toxicity 
(Table 7.1).
Table 7.1 Classification of AMPs
Structure AMPs
Linear, no Cys Cecropin A
Cys residues Defensins
Rich in specific amino acids (proline, glycine, histidine, 
tryptophan)
PR39 (proline rich), Indolicidin 
(tryptophan rich)
Fig. 7.1 The three model mechanisms of interaction between AMPs and biologic membranes. The 
image was modified from Chan et al. (2006). (a) Barrel/stave model. The AMPs form a pore in the 
membrane. (b) Torroidal pore. After massive AMP accumulation at the membrane surface, some 
AMPs acquire a transmembrane orientation and form pores, which have mixed composition (phos-
pholipids and peptides). A curvature is induced in the membrane. (c) Carpet-like mechanism. The 
membrane surface, covered by AMPs, undergoes disruption
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2  Antimicrobial Peptides in Malaria
Some AMPs of different origin are known to affect Plasmodium development in 
different phases of the biological cycle, from asexual blood stages (cecropin, melit-
tin, magainin, dermaseptin S4) to sexual stages in the mosquito, where AMPs can 
block ookinetes viability (VIDA 1-3, scorpine) or oocyst formation (VIDA 1-3) 
(Bell 2011). A recent work by Carter and colleagues investigated the effect of 33 
AMPs on Plasmodium early sporogonic stages, verifying that they did not alter 
mosquitoes’ fitness (Carter et al. 2013). Table 7.2 summarizes the antiplasmodial 
activity of some AMPs.
The secondary structure of AMPs has been used to predict the activity on differ-
ent Plasmodium stages. For instance, Arrighi and colleagues designed new AMPs 
starting from natural or synthetic antimicrobial polypeptides and observed that pep-
tides with no particular secondary structures (containing mainly random coils and 
turns) were more active on the sporogonic stages of P. berghei and P. yoelii (Arrighi 
et al. 2002).
Some antimalarial AMPs are hemolytic or toxic, whereas others specifically act 
on the membrane of infected red blood cells (RBCs) or directly on the membrane 
of the parasite and not on the membrane of uninfected RBCs. An example is given 
by dermaseptin S4, which is hemolytic and disrupts uninfected RBCs too. 
Development of more selective substitutes was necessary to decrease toxicity 
(Krugliak et al. 2000).
Table 7.2 Antimalarial activity of some representative AMPs
Activity AMPs Target References
Inhibition of 
Plasmodium in vitro
Dermaseptin S4  
(μM range)
Erythrocytic stages, 
especially 
trophozoites
Dagan et al. (2002), 
Ghosh et al. (1997), 
Krugliak et al. (2000)
Vida 1-3 Ookinetes of Pb and 
Py
Arrighi et al. (2002)
Scorpine Pb ookinetes 
formation; asexual 
parasites
Carballar-Lejarazú 
et al. (2008), Conde 
et al. (2000)
Cecropin, melittin, 
magainin e cecropin–
melittin hybrids
Bloodstream forms Boman et al. (1989), 
Gwadz et al. (1989), 
Wade et al. (1990)
Block malaria 
transmission in 
mosquitoes
Vida 1-3 Oocyst formation, 
Pb ookinetes in vitro, 
Pb and Pf sporogonic 
stages in mosquito
Arrighi et al. (2002), 
Carter et al. (2013)
Defensin Oocyst development Shahabuddin et al. 
(1998)
Melittin Pb ookinetes in vitro, 
Pb and Pf sporogonic 
stages in mosquito
Carter et al. (2013)
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2.1  Antimalarial AMPs Source
Antimalarial AMPs can be produced by mammalian hosts and mosquito vectors, as 
well as other organisms, which are not related to malaria (Table 7.3).
AMPs are part of the immune defense of mosquitoes, and Plasmodium infection 
can modulate AMPs expression in the Anopheles mosquito (Fig. 7.2). Vizioli and 
Table 7.3 Sources of representative antimalarial AMPs
AMPs Origin
Human Defensin
Mosquito Defensin A. gambiae
Gambicin A. gambiae
Cecropins A. gambiae
Other organisms Metalnikowin Palomena prasina
Scorpine venom of Pandinus imperator
Cecropin A Hyalophora cecropia—Cecropia moth
Magainin 2 Skin and stomach of Xenopus laevis
Fig. 7.2 The insect immune 
response to microorganisms. 
Common immune pathways 
in Drosophila and Anopheles. 
Proteins known in Drosophila 
with unknown ortholog in 
Anopheles are defined  
as “X?”
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colleagues demonstrated that Anopheles mosquitoes fed upon mice infected with 
P. berghei expressed higher mRNA levels of cecropin A compared to mosquitoes 
fed with parasites unable to develop in the insect (Vizioli et al. 2000). Another 
example is described by Herrera-Ortiz and colleagues, who demonstrated that the 
mRNAs of attacin, cecropin, and gambacin were overexpressed in the midgut and 
abdominal tissue of mosquitoes fed with P. berghei-infected mouse blood (Herrera-
Ortiz et al. 2011).
The majority of AMPs with antimalarial activity described by Carter and col-
leagues were derived from bee/wasp venoms (Carter et al. 2013).
Other examples of organisms producing AMPs with antimalarial activity are 
the scorpio Pandinus imperator, from which scorpine was isolated; the Cecropia 
moth which produces Cecropins; and Xenopus laevis, from which Magainin was 
extracted.
2.2  Defensins
Defensins represent the most important human AMPs as they are present at high 
concentrations (up to millimolar ranges) in epithelial and phagocytic cells. Their 
structure is characterized by a fold rich in beta-sheets and disulfide bonds between 
pairs of cysteines. The direct role of human defensins in malaria is not clear. 
Overexpression of a rat defensin (NP-1) was observed in a rat malaria model. Such 
enhancement was associated to protection of the young rats from lethal infection. 
That work supported a role for defensin in the immunity reaction to malaria infec-
tion (Pierrot et al. 2007). However, no direct studies on human defensins and malaria 
have been published.
Defensins are also part of the immune system of mosquitoes: their structure dif-
fers from that of human defensins, since it contains an alpha-helix linked to a beta- 
sheet. The role of mosquito defensins in malaria infection is better described 
compared to human defensins (Dixit et al. 2008; Hoffmann 1997; Meredith et al. 
2008). Defensin expression, constitutive in mosquitoes midgut, is further induced 
by malaria infection (Richman et al. 1997; Vizioli et al. 2001b). The injection of 
defensin in Aedes egypti inhibited the development of Plasmodium sexual stages, 
resulting in oocyst abnormal development (Shahabuddin et al. 1998). The treatment 
of sporozoites with defensin decreased their viability.
However, a reverse genetic approach demonstrated that defensin is not necessary 
in A. gambiae (Blandin et al. 2002). The gene of defensin was disrupted in A. gam-
biae by treatment with dsRNA. This knockdown approach decreased the mosquito 
resistance to bacterial infections but did not alter the ookinete/oocyst formation or 
oocyst number after infection with P. berghei.
7 Beyond Lysozyme: Antimicrobial Peptides Against Malaria
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
96
2.3  Scorpine
Scorpion venom is a rich source of peptides with different pharmacological 
 activities. Interestingly, AMPs have been found in scorpion venom, and they may 
have different functions: the defense of scorpions from bacterial infection, the 
immobilization of their prey, or the synergistic activity with other venom toxins 
(Simard and Watt 1990).
In particular, scorpine (amino acid sequence in Table 7.4) is extracted from the 
venom of the scorpion Pandinus imperator. It was tested for the first time against 
Plasmodium due to its similarity, in the peptide sequence, to cecropins and defen-
sins, already known for their antimalarial activity (Conde et al. 2000).
Scorpine decreased in a dose-dependent manner the fecundation of P. berghei 
parasites (measured as number of rosettes) and the formation of ookinetes (Conde 
et al. 2000). The inhibition of ookinetes formation in P. berghei was confirmed by 
Carballar-Lejarazù and colleagues, who also demonstrated the inhibition of asexual P. 
falciparum parasites in vitro (Carballar-Lejarazú et al. 2008). The authors used 
recombinant scorpine produced by transfected A. gambiae cells (cell line Sua 5.1). 
The plasmid for transfection was designed in order to make scorpine expressed under 
the control of the A. gambiae serpin promoter. They also created transgenic Drosophila, 
demonstrating that the expression of scorpine is not toxic to the insect. Such a paper 
was proposed as a proof of concept for the development of recombinant mosquitoes, 
an approach already proposed by Possani et al. (2002), as described below.
2.4  Cecropins, Melittin, and Cecropin–Melittin Hybrids
Cecropins are a group of insect-derived inducible antibiotic peptides from the 
giant silk moth Hyalophora cecropia. Cecropins A and B AMPs were fully charac-
terized by Boman and colleagues, a work published by Nature and reproduced on 
Table 7.4 Amino acid sequence of the major antimalarial AMPs discussed in this chapter
Name Amino acid sequence
Scorpine GWINEEKIQKKIDERMGNTVLGGMAKAIVHKMAKNEFQCM 
ANMDMLGNCEKHCQTSGEKGYCHGTKCKCGTPLSY
Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK
Melittin GIGAVLKVLTTGLPALISWIKRKRQQ
CA(1-13) M(1-13) KWKLFKKIEKVGQGIGAVLKVLTTGL
CA(1-8) M(1-18) KWKLFKKIGIGAVLKVLTTGLPALIS
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS
Dermaseptin S4 ALWMTLLKKVLKAAAKAALNAVLVGANA
Gambicin MVFAYAPTCARCKSIGARYCGYGYLNRKGVSCDGQTTINSCE 
DCKRKFGRCSDGFITECFL
CA cecropin A, M melittin
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The Journal of Immunology representing a pillar article in immunology (Steiner 
et al. 2009) (see Fig. 7.3 for cecropin structure). Cecropin B affected oocyst devel-
opment in the A. gambiae - P. cynomolgi model (Gwadz et al. 1989). Some deriva-
tives, namely Shiva-1, Shiva-2, and Shiva-3, were designed starting from the 
cecropin amino acidic sequence (Rodriguez et al. 1995; Yoshida et al. 2001). They 
inhibited the sexual stages of P. berghei as well as ookinete and sporozoite develop-
ment in the mosquito model.
The structural conformation of melittin was described by Wade and colleagues 
as percentages of alpha-helixes, beta-sheet, and random coils (Wade et al. 1990).
Few years later the possibility of improving the antibacterial and antimalarial 
activities by creating hybrids between cecropin and melittin was explored (Boman 
et al. 1989). The properties of cecropins along with melittin and megainin to form 
ion channels in biologic membranes were studied in the 1990s (Wade et al. 1990). 
The amino acidic sequence of cecropin A, melittin, and two hybrids is reported in 
Table 7.4.
2.5  Magainin
Magainins were originally isolated from the skin of the African clawed frog 
Xenopus laevis (Zasloff 1987). Magainin (amino acidic sequence in Table 7.4) is 
active against different bacteria, such as Escherichia coli, Streptococcus pyogenes, 
and Pseudomonas aeruginosa, by forming pores in the membranes. Magainin 
affects the viability of others microorganisms, including Saccharomyces cerevi-
siae and Plasmodium spp (Gwadz et al. 1989). Some derivatives were developed. 
However, none of them were approved by FDA after clinical trials since they did 
not display increased activity compared to existing antibacterials or because they 
implicated toxicity issues. The structural conformation as percentages of alpha-
helixes, beta-sheet, and random coils (see Fig. 7.4) was described by Wade and 
colleagues (Wade et al. 1990).
Fig. 7.3 Structure of 
cecropin. Image from the 
PFAM protein database 
(Punta et al. 2012) of the 
Wellcome Trust Sanger, 
Hinxton, UK (http://pfam.
sanger.ac.uk/family/
Cecropin)
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2.6  Dermaseptins
Dermaseptins are a family of AMPs isolated from frogs of the Phyllomedusa genus 
with cytolytic activity against bacteria, protozoa, yeast, and filamentous fungi. 
Ghosh and colleagues compared hemolytic dermaseptin S4 (amino acidic sequence 
in Table 7.4) with nonhemolytic dermaseptin S3 for their physical properties (aggre-
gation in solution and dissociation in membranes, binding to and interaction with 
RBCs) and for the effect on P. falciparum growth in vitro (Ghosh et al. 1997). 
Several derivatives were prepared starting from dermaseptin S4, with many show-
ing a selective activity on the membrane of infected RBCs compared to the activity 
on the membranes of normal RBCs (Krugliak et al. 2000). The effects of derma-
septin S4 and its derivatives on malaria parasites were further investigated with 
respect to stage specificity (Dagan et al. 2002; Efron et al. 2002).
2.7  Gambicin
Gambicin (amino acidic sequence in Table 7.4) was first isolated from the condi-
tioned medium of the Anopheles gambiae cell lines 4a-3A and 4a-3B (Vizioli 
et al. 2001a). The activity on different microorganism was tested and gambicin 
inhibited the growth of Micrococcus luteus, E. coli SBS363, and Neurospora 
crassa. Gambicin was also effective against P. berghei ookinetes. Moreover, as 
other AMPs, the expression of gambicin was enhanced by Plasmodium infection. 
In 2006, Dong and colleagues studied the immune response of Anopheles gam-
biae to the human P. falciparum or the murine P. berghei malaria parasites (ooki-
nete stage) by DNA microarray analyses and RNAi gene silencing assays (Dong 
et al. 2006). The two species induced the expression of different genes and the 
authors confirmed the different ability to modulate the mosquito immune response 
to malaria.
Fig. 7.4 NMR structure of magainin-2 in DPC micelles, ten structures. Picture from the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (Berman et al. 2000). 
Protein chains are colored from the N-terminal to the C-terminal using a rainbow (spectral) color 
gradient (http://www.rcsb.org/pdb/explore/explore.do?pdbId=2MAG)
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2.8  Other Antimalarial AMPs
A possible classification of antimalarial AMPs is described by Bell (2011). Cationic, 
amphipathic “host-defense” peptides such as defensins and cecropins were treated 
in this chapter. Other membrane-active peptide antibiotics, such as gramicidin, have 
high activity on Plasmodium in the nanomolar range but they are also toxic for 
mammalian cells. Cyclosporine A, representative of the hydrophobic peptides class, 
was studied in all the Plasmodium stages and is active especially in the murine 
models. Thiopeptides, such as thiostrepton, have antimalarial activity but quite high 
IC50. Some other naturally occurring or synthetic peptides have been shown to have 
antimalarial activity. The antiprotozoal activity of AMPs from amphibian origin 
was reviewed by Rivas and colleagues (Rivas et al. 2009).
3  Potential Application of AMPs in Malaria  
Research and Control
AMPs have been investigated as potential drugs against different Plasmodium 
stages and in particular against the erythrocytic phase, which is largely associated 
with the symptoms of the disease (Khadjavi et al. 2010). Recently, the interest of the 
research community and health authorities has moved toward elimination/eradica-
tion programs. To reach this ambitious goal, blocking transmission becomes an 
important step and AMPs could be reevaluated for their activities against the sexual 
stages, occurring throughout the mosquito vector.
The most described application for AMPs in malaria is mosquito and parasite 
engineering to reduce or interrupt malaria parasite transmission (Carter and Hurd 
2010). Possani and colleagues proposed to insert the genetic code for bioactive pep-
tides extracted from scorpion venom (scorpine mainly) into Anopheles mosquitoes 
to make them resistant to malaria infection (Possani et al. 2002). The authors started 
from evidence from the literature that P. gallinaceum ookinetes injected in 
Drosophila melanogaster were able to develop into sporozoites identical to those 
obtained in mosquitoes and, as expected, able to infect chickens. They designed a 
strategy involving Drosophila as an investigation tool to study AMPs toxicity 
against insects and Plasmodium development within the insect. However, the 
authors did not go beyond the design of this strategy and did not show results of the 
transgenic work, only referring to preliminary, encouraging results.
A big issue with these transgenesis approaches is represented by the ethical con-
cern in releasing transgenic insects in the environment.
A different approach is to engineer those microorganisms living in mosquitos’ 
midgut. In this case, the aim is to make the vector resistant to malaria parasites. 
Metarhizium anisopliae fungi were transfected with salivary gland and midgut pep-
tide 1 (SM1), scorpine, or an antibody that agglutinates sporozoites. Mosquitoes 
were infected with this microorganism, leading to a reduction of sporozoites 
 production by more than 50 %, with the best result, 98 % reduction, obtained with 
scorpine (Fang et al. 2011).
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